NCT00220818

A Study to Evaluate the Effect of Lansoprazole on Infants With Gastroesophageal Reflux Disease.

A Phase 1, Single- and Repeated-Dose, Randomized, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Lansoprazole in Infants With Clinically-Evident Gastroesophageal Reflux Disease.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Takeda · Industry
• Sex: All
• Age: 29 Days – 364 Days
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to understand how quickly lansoprazole, once daily (QD), improves feeding in premature babies or babies less than 28 days of age.

Detailed description

A Phase 1, multicenter, pharmacokinetic/Pharmacodynamic and safety study in which infants will be randomized in an open-label fashion to receive 5 days of open-label treatment with lansoprazole pediatric suspension 1 mg/kg/day oral, or lansoprazole pediatric suspension 2 mg/kg/day oral. On Dosing Days 1 and 5, blood samples will be obtained for drug assay. All subjects will be evaluated for inclusion in the pH monitoring portion of the study and will undergo pH monitoring, provided it is clinically indicated, at the discretion of the investigator. Intragastric pH monitoring (up to 24 hours) will be performed at Baseline, on Dosing Day 1 (or Day 2) and on Dosing Day 5 (or Day 6). Intraesophageal pH may be done in addition to intragastric pH at the discretion of the investigator. Subjects will be evaluated for safety, including a follow-up visit on Post-Dosing Day 14.

Conditions

• Gastroesophageal Reflux Disease

Interventions

Type	Name	Description
DRUG	Lansoprazole	Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.
DRUG	Lansoprazole	Lansoprazole 2.0 mg/kg/day suspension, orally, once daily for up to 5 days.

Timeline

• Start date: 2005-01-01
• Primary completion: 2005-07-01
• Completion: 2005-07-01
• First posted: 2005-09-22
• Last updated: 2010-07-22